Patents by Inventor Alain Tissot

Alain Tissot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200216880
    Abstract: Herein is reported a method for selecting a variant of a parental antibody variable domain encoding nucleic acid, wherein the parental antibody variable domain amino acid sequence encoded by said encoding nucleic acid has at least one developability hot spot, the method comprising the steps of (i) providing a multitude of DNA-containing samples (genomic material of antibody secreting B-cell) each including one or more antibody variable domain encoding nucleic acids; (ii) performing PCR amplification of said antibody variable domain encoding nucleic acids of (i) using consensus sequence-specific primers to obtain amplification products (wherein said consensus sequence-specific primers bind to consensus sequences that are common to a plurality of genes within the genetic loci set, thereby generating a pool of amplification products); (iii) sequencing a plurality of said amplification products obtained in step (ii) in order to determine the relative proportion of each nucleotide at each position in a sequencing
    Type: Application
    Filed: September 5, 2019
    Publication date: July 9, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Guy GEORGES, Stefan KLOSTERMANN, Alain TISSOT, Francesca ROS, Alexander BUJOTZEK, Clemens WRZODEK, Frederic SCHULTZ
  • Publication number: 20190276530
    Abstract: The present invention relates to blood brain barrier shuttles that bind receptors on the blood brain barrier (R/BBB) and methods of using the same.
    Type: Application
    Filed: December 19, 2018
    Publication date: September 12, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Bernd Bohrmann, Per-Ola Freskgard, Peter Maier, Jens Niewoehner, Alain Tissot-Daguette, Eduard Urich
  • Patent number: 9950055
    Abstract: The invention relates to the finding that virus like particles (VLPs) can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs). Such CpG-VLPs are dramatically more immunogenic than their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against antigens optionally coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against the VLP itself. In addition, the T cell responses against both the VLPs and antigens are especially directed to the Th1 type. Antigens attached to CpG-loaded VLPs may therefore be ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases.
    Type: Grant
    Filed: January 23, 2014
    Date of Patent: April 24, 2018
    Assignee: KUROS BIOSCIENCES AG
    Inventors: Martin F. Bachmann, Tazio Storni, Patrik Maurer, Alain Tissot, Katrin Schwarz, Edwin Meijerink, Gerd Lipowsky, Paul Pumpens, Indulis Cielens, Regina Renhofa
  • Publication number: 20180036399
    Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.
    Type: Application
    Filed: January 17, 2017
    Publication date: February 8, 2018
    Applicant: KUROS BIOSCIENCES AG
    Inventors: Wolfgang A. Renner, Martin Bachmann, Alain Tissot, Patrick Maurer, Franziska Lechner, Peter Sebbel, Christine Piossek
  • Publication number: 20160008453
    Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.
    Type: Application
    Filed: November 14, 2014
    Publication date: January 14, 2016
    Applicant: CYTOS BIOTECHNOLOGY AG
    Inventors: WOLFGANG A. RENNER, Martin Bachmann, Alain Tissot, Patrick Maurer, Franziska Lechner, Peter Sebbel, Christine Piossek
  • Publication number: 20150374807
    Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular an A?1-peptide-VLP-composition. More specifically, the invention provides a composition comprising a virus-like particle and at least one A?1-6 peptide bound thereto. The invention also provides a process for producing the conjugates and the ordered and repetitive arrays, respectively. The compositions of the invention are useful in the production of vaccines for the treatment of Alzheimer's disease and as a pharmaccine to prevent or cure Alzheimer's disease and to efficiently induce immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune, responses within the indicated context.
    Type: Application
    Filed: July 1, 2015
    Publication date: December 31, 2015
    Applicant: Novartis AG
    Inventors: Martin F. Bachmann, Alain Tissot, Rainer Ortmann, Rainer Martin Lueoend, Matthias Staufenbiel, Peter Frey
  • Publication number: 20150322149
    Abstract: The present invention relates to blood brain barrier shuttles that bind receptors on the blood brain barrier (R/BBB) and methods of using the same.
    Type: Application
    Filed: February 2, 2015
    Publication date: November 12, 2015
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Bernd Bohrmann, Per-Ola Freskgard, Peter Maier, Jens Niewoehner, Alain Tissot-Daguette, Eduard Urich
  • Publication number: 20150202281
    Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.
    Type: Application
    Filed: May 30, 2013
    Publication date: July 23, 2015
    Applicants: CYTOS BIOTECHNOLOGY AG, NOVARTIS PHARMA AG
    Inventors: Wolfgang A. RENNER, Martin Bachmann, Alain Tissot, Patrick Maurer, Franziska Lechner, Peter Sebbel, Christine Piossek, Rainer Ortmann, Rainer Lüönd, Matthias Staufenbiel, Peter Frey
  • Publication number: 20150030620
    Abstract: The invention relates to the finding that virus like particles (VLPs) can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs). Such CpG-VLPs are dramatically more immunogenic than their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against antigens optionally coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against the VLP itself. In addition, the T cell responses against both the VLPs and antigens are especially directed to the Th1 type. Antigens attached to CpG-loaded VLPs may therefore be ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases.
    Type: Application
    Filed: January 23, 2014
    Publication date: January 29, 2015
    Applicant: CYTOS BIOTECHNOLOGY AG
    Inventors: MARTIN F. BACHMANN, Tazio STORNI, Patrick MAURER, Alain TISSOT, Katrin SCHWARZ, Edwin MEIJERINK, Gerd LlPOWSKY, Paul PUMPENS, Indulis CIELENS, Regina RENHOFA
  • Publication number: 20140294876
    Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular an A?1-6 peptide-VLP-composition. More specifically, the invention provides a composition comprising a virus-like particle and at least one A?1-6 peptide bound thereto. The invention also provides a process for producing the conjugates and the ordered and repetitive arrays, respectively. The compositions of the invention are useful in the production of vaccines for the treatment of Alzheimer's disease and as a pharmaccine to prevent or cure Alzheimer's disease and to efficiently induce immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.
    Type: Application
    Filed: December 13, 2013
    Publication date: October 2, 2014
    Applicant: NOVARTIS AG
    Inventors: Martin F. BACHMANN, Alain TISSOT, Rainer ORTMANN, Rainer LUEOEND, Matthias STAUFENBIEL, Peter FREY
  • Patent number: 8691209
    Abstract: The invention relates to the finding that virus like particles (VLPs) can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs). Such CpG-VLPs are dramatically more immunogenic than their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against antigens optionally coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against the VLP itself. In addition, the T cell responses against both the VLPs and antigens are especially directed to the Th1 type. Antigens attached to CpG-loaded VLPs may therefore be ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases.
    Type: Grant
    Filed: November 10, 2011
    Date of Patent: April 8, 2014
    Assignee: Cytos Biotechnology AG
    Inventors: Martin F. Bachmann, Tazio Storni, Patrik Maurer, Alain Tissot, Katrin Schwarz, Edwin Meijerink, Gerd Lipowsky, Paul Pumpens, Indulis Cielens, Regina Renhofa
  • Publication number: 20140056933
    Abstract: The application is related to compositions and methods for the treatment of hypersensitivity, wherein the compositions comprise a particle packaged with immunostimulatory nucleic acids. The compositions of the invention are particularly useful in the treatment of atopic eczema, asthma and IgE-mediated allergy (type I allergy), especially pollen allergy and house dust allergy.
    Type: Application
    Filed: July 22, 2013
    Publication date: February 27, 2014
    Inventors: Wolfgang Renner, Martin F. Bachmann, Indulis Cielens, Conrad Johannes Coester, Klaus Dietmeier, Sebastian Fuchs, Vania Manolova, Patrik Maurer, Paul Pumpens, Regina Renhofa, Alain Tissot, Yu Zou
  • Publication number: 20130315949
    Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.
    Type: Application
    Filed: December 7, 2012
    Publication date: November 28, 2013
    Applicant: Cytos Biotechnology AG
    Inventors: Wolfgang A. RENNER, Martin Bachmann, Alain Tissot, Patrick Maurer, Franziska Lechner, Peter Sebbel, Christine Piossek
  • Patent number: 8574564
    Abstract: The application is related to compositions and methods for the treatment of hypersensitivity, wherein the compositions comprise a particle packaged with immunostimulatory nucleic acids. The compositions of the invention are particularly useful in the treatment of atopic eczema, asthma and IgE-mediated allergy (type I allergy), especially pollen allergy and house dust allergy.
    Type: Grant
    Filed: October 8, 2009
    Date of Patent: November 5, 2013
    Assignee: Cytos Biotechnology AG
    Inventors: Wolfgang A. Renner, Martin F. Bachmann, Indulis Cielens, Conrad Johannes Coester, Klaus Dietmeier, Sebastian Fuchs, Vania Manolova, Patrik Maurer, Paul Pumpens, Regina Renhofa, Alain Tissot, Yu Zou
  • Publication number: 20130230484
    Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen array, wherein the antigen is an IL-1 protein, an IL-1 mutein or an IL-1 fragment. More specifically, the invention provides a composition comprising a virus-like particle, and at least one IL-1 protein, IL-1 mutein or at least one IL-1 fragment linked thereto. The invention also provides a process for producing the composition. The compositions of the invention are useful in the production of vaccines for the treatment of inflammatory diseases, and chronic autoimmune diseases, genetic diseases and cardiovascular diseases. The composition of the invention efficiently induces immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.
    Type: Application
    Filed: August 1, 2012
    Publication date: September 5, 2013
    Applicant: Cytos Biotechnology AG
    Inventors: Martin BACHMANN, Gunther Spohn, Alain Tissot
  • Patent number: 8449874
    Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen array, wherein the antigen is an IL-1 mutein. More specifically, the invention provides a composition comprising a virus-like particle, and at least one IL-1 mutein linked thereto. The invention also provides a process for producing the composition. The compositions of the invention are useful in the production of vaccines for the treatment of inflammatory diseases, and chronic autoimmune diseases, genetic diseases and cardiovascular diseases. The composition of the invention efficiently induces immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.
    Type: Grant
    Filed: March 29, 2007
    Date of Patent: May 28, 2013
    Assignee: Cytos Biotechnology AG
    Inventors: Martin F. Bachmann, Gunther Spohn, Alain Tissot
  • Publication number: 20120301499
    Abstract: The invention relates to the finding that virus like particles (VLPs) can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs). Such CpG-VLPs are dramatically more immunogenic than their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against antigens optionally coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against the VLP itself. In addition, the T cell responses against both the VLPs and antigens are especially directed to the Th1 type. Antigens attached to CpG-loaded VLPs may therefore be ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases.
    Type: Application
    Filed: November 10, 2011
    Publication date: November 29, 2012
    Applicant: CYTOS BIOTECNOLOGY AG
    Inventors: MARTIN BACHMANN, TAZIO STORNI, PATRIK MAURER, ALAIN TISSOT, KATRIN SCHWARZ, EDWIN MEIJERINK, GERD LIPOWSKY, PAUL PUMPENS, INDULIS CIELENS, REGINA RENHOFA
  • Publication number: 20120114674
    Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.
    Type: Application
    Filed: April 28, 2011
    Publication date: May 10, 2012
    Applicants: NOVARTIS PHARMA AG, CYTOS BIOTECHNOLOGY AG
    Inventors: Wolfgang A. Renner, Martin Bachmann, Alain Tissot, Patrick Maurer, Franziska Lechner, Peter Sebbel, Christine Piossek, Rainer Ortmann, Rainer Lüönd, Matthias Staufenbiel, Peter Frey
  • Publication number: 20110305723
    Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses.
    Type: Application
    Filed: December 23, 2010
    Publication date: December 15, 2011
    Applicant: Cytos Biotechnology AG
    Inventors: Wolfgang A. Renner, Martin Bachmann, Alain Tissot, Patrick Maurer, Franziska Lechner, Peter Sebbel, Christine Piossek
  • Publication number: 20110091411
    Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen array, wherein the antigen is an IL-1 mutein. More specifically, the invention provides a composition comprising a virus-like particle, and at least one IL-1 mutein linked thereto. The invention also provides a process for producing the composition. The compositions of the invention are useful in the production of vaccines for the treatment of inflammatory diseases, and chronic autoimmune diseases, genetic diseases and cardiovascular diseases. The composition of the invention efficiently induces immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.
    Type: Application
    Filed: March 29, 2007
    Publication date: April 21, 2011
    Applicant: Cytos Biotechnology AG
    Inventors: Martin F. Bachmann, Gunther Spohn, Alain Tissot